Noninferiority of Local Control and Comparable Toxicity of Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Breast Cancer: 5-Year Results of the IMRT-MC2 Phase III Trial
International Journal of Radiation Oncology*Biology*Physics · 2023
DOI: 10.1016/j.ijrobp.2023.05.035 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023. Verfasst von Tobias Forster und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, German…. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiotherapy, Intensity-Modulated, Radiotherapy, Conformal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: The IMRT-MC2 trial was conducted to demonstrate the noninferiority of conventionally fractionated intensity modulated radiation therapy with a simultaneous integrated boost to 3-dimensional conformal radiation therapy with a sequential boost for adjuvant breast radiation therapy. METHODS AND MATERIALS: A total of 502 patients were randomized between 2011 and 2015 for the prospective, multicenter, phase III trial (NCT01322854). Five-year results of late toxicity (late effects normal tissue task force-subjective, objective, management, and analytical), overall survival, disease-free survival, distant disease-free survival, cosmesis (Harvard scale), and local control (noninferiority margin at hazard ratio [HR] of 3.5) were analyzed after a median follow-up of 62 months. RESULTS: The 5-year local control rate for the intensity modulated radiation therapy with simultaneous integrated boost arm was non-inferior to the control arm (98.7% vs 98.3%, respectively; HR, 0.582; 95% CI, 0.119-2.375; P = .4595). Furthermore, there was no significant difference in overall survival (97.1% vs 98.3%, respectively; HR, 1.235; 95% CI, 0.472-3.413; P = .6697), disease-free survival (95.8% vs 96.1%, respectively; HR, 1.130; 95% CI, 0.487-2.679; P = .7758), and distant disease-free survival (97.0% vs 97.8%, respectively; HR, 1.667; 95% CI, 0.575-5.434; P = .3601). After 5 years, late toxicity evaluation and cosmetic assessment further showed no significant differences between treatment arms. CONCLUSIONS: The 5-year results of the IMRT-MC2 trial provide strong evidence that the application of conventionally fractionated simultaneous integrated boost irradiation for patients with breast cancer is both safe and effective, with noninferior local control compared with 3-dimensional conformal radiation therapy with sequential boost.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany.
- Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Radiation Oncology, Eberhard-Karls-University Tuebingen, Tuebingen, Germany.
- Division of Biostatistics, Coordination Centre for Clinical Trials, University of Heidelberg, Heidelberg, Germany.
- Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany.
- Strahlentherapie Rhein-Pfalz, Neustadt, Germany.
Zitieren
APA
Forster, T., Köhler, C., Dorn, M., Häfner, M. F., Arians, N., König, L., Harrabi, S. B., Schlampp, I., Weykamp, F., Meixner, E., Lang, K., Heinrich, V., Weidner, N., Hüsing, J., Wallwiener, M., Golatta, M., Hennigs, A., Heil, J., Hof, H., …, & Hörner-Rieber, J. (2023). Noninferiority of Local Control and Comparable Toxicity of Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Breast Cancer: 5-Year Results of the IMRT-MC2 Phase III Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.05.035
Vancouver
Forster T, Köhler C, Dorn M, Häfner MF, Arians N, König L, et al. Noninferiority of Local Control and Comparable Toxicity of Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Breast Cancer: 5-Year Results of the IMRT-MC2 Phase III Trial. International Journal of Radiation Oncology*Biology*Physics. 2023. doi:10.1016/j.ijrobp.2023.05.035
BibTeX
@article{Forster2023,
author = {Forster, Tobias and Köhler, Clara and Dorn, Melissa and Häfner, Matthias Felix and Arians, Nathalie and König, Laila and Harrabi, Semi Ben and Schlampp, Ingmar and Weykamp, Fabian and Meixner, Eva and Lang, Kristin and Heinrich, Vanessa and Weidner, Nicola and Hüsing, Johannes and Wallwiener, Markus and Golatta, Michael and Hennigs, André and Heil, Jörg and Hof, Holger and Krug, David and Debus, Jürgen and Hörner-Rieber, Juliane},
title = {Noninferiority of Local Control and Comparable Toxicity of Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Breast Cancer: 5-Year Results of the IMRT-MC2 Phase III Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2023},
doi = {10.1016/j.ijrobp.2023.05.035}
}
EUVIMED